mRNA Vaccines Against COVID-19 as Trailblazers for Other Human Infectious Diseases DOI Creative Commons
Rossella Brandi, Alessia Paganelli, Raffaele D’Amelio

и другие.

Vaccines, Год журнала: 2024, Номер 12(12), С. 1418 - 1418

Опубликована: Дек. 16, 2024

mRNA vaccines represent a milestone in the history of vaccinology, because they are safe, very effective, quick and cost-effective to produce, easy adapt should antigen vary, able induce humoral cellular immunity. Methods: To date, only two COVID-19 one RSV have been approved. However, several currently under development for prevention human viral (influenza, immunodeficiency virus [HIV], Epstein–Barr virus, cytomegalovirus, Zika, respiratory syncytial metapneumovirus/parainfluenza 3, Chikungunya, Nipah, rabies, varicella zoster herpes simplex 1 2), bacterial (tuberculosis), parasitic (malaria) diseases. Results: RNA viruses, such as severe acute syndrome coronavirus (SARS-CoV)-2, HIV, influenza, characterized by high variability, thus creating need rapidly circulating strain, task that can easily accomplish; however, speed variability may be higher than time needed vaccine adapted. vaccines, using lipid nanoparticles delivery system, act adjuvants, powerfully stimulating innate well adaptive immunity, both humoral, which is waning, cell-mediated, highly persistent. Safety profiles were satisfactory, considering slight increase prognostically favorable anaphylactic reactions young females myopericarditis males has observed. Conclusions: The pandemic determined shift use RNA: after having used medicine micro-RNAs tumor new era anti-infectious begun, great development, either improve already available, but unsatisfactory, or develop protective against infectious agents no preventative tools realized yet.

Язык: Английский

Validation and Clinical Performance of a Non-Commercial ELISA for SARS-CoV-2 Anti-RBD IgA Antibodies DOI

Sheila Chávez-Valdés,

Ana K Marichal-Rodríguez,

Yahima Chacón-Quintero

и другие.

Analytical Biochemistry, Год журнала: 2025, Номер 700, С. 115787 - 115787

Опубликована: Янв. 31, 2025

Язык: Английский

Процитировано

0
The single-dose Janssen Ad26.COV2.S COVID-19 vaccine elicited robust and persistent anti-spike IgG antibody responses in a 12-month Ugandan cohort DOI Creative Commons
Jennifer Serwanga,

Laban Kato,

Gerald Kevin Oluka

и другие.

Frontiers in Immunology, Год журнала: 2024, Номер 15

Опубликована: Май 8, 2024

Introduction The study investigation examined the immune response to Janssen Ad26.COV2.S COVID-19 vaccine within a Ugandan cohort, specifically targeting antibodies directed against spike (S) and nucleocapsid (N) proteins. We aimed examine durability robustness of induced antibody while also assessing occurrences breakthrough infections previous anti-Spike seropositivity SARS-CoV-2. Methods included 319 specimens collected over 12 months from 60 vaccinees aged 18 64. Binding were quantified using validated ELISA method measure SARS-CoV-2-specific IgG, IgM, IgA levels S N Results results showed that baseline for S-IgG was high at 67%, increasing 98% by day 14 consistently stayed above 95% up months. However, S-IgM responses remained suboptimal. A raised S-IgA rate seen doubled 40% 86% just two weeks following initial dose, indicating sustained robust peripheral immunity. An increase in N-IgG nine post-vaccination suggested eight cases. Baseline cross-reactivity influenced spike-directed responses, with individuals harbouring showing notably higher responses. Discussion Robust long lasting infection-induced observed, significant implications regions where administering subsequent doses poses logistical challenges.

Язык: Английский

Процитировано

0
mRNA Vaccines Against COVID-19 as Trailblazers for Other Human Infectious Diseases DOI Creative Commons
Rossella Brandi, Alessia Paganelli, Raffaele D’Amelio

и другие.

Vaccines, Год журнала: 2024, Номер 12(12), С. 1418 - 1418

Опубликована: Дек. 16, 2024

mRNA vaccines represent a milestone in the history of vaccinology, because they are safe, very effective, quick and cost-effective to produce, easy adapt should antigen vary, able induce humoral cellular immunity. Methods: To date, only two COVID-19 one RSV have been approved. However, several currently under development for prevention human viral (influenza, immunodeficiency virus [HIV], Epstein–Barr virus, cytomegalovirus, Zika, respiratory syncytial metapneumovirus/parainfluenza 3, Chikungunya, Nipah, rabies, varicella zoster herpes simplex 1 2), bacterial (tuberculosis), parasitic (malaria) diseases. Results: RNA viruses, such as severe acute syndrome coronavirus (SARS-CoV)-2, HIV, influenza, characterized by high variability, thus creating need rapidly circulating strain, task that can easily accomplish; however, speed variability may be higher than time needed vaccine adapted. vaccines, using lipid nanoparticles delivery system, act adjuvants, powerfully stimulating innate well adaptive immunity, both humoral, which is waning, cell-mediated, highly persistent. Safety profiles were satisfactory, considering slight increase prognostically favorable anaphylactic reactions young females myopericarditis males has observed. Conclusions: The pandemic determined shift use RNA: after having used medicine micro-RNAs tumor new era anti-infectious begun, great development, either improve already available, but unsatisfactory, or develop protective against infectious agents no preventative tools realized yet.

Язык: Английский

Процитировано

0